| Keywords: |
cancer survival; primary tumor; gene mutation; clinical feature; cancer recurrence; bevacizumab; solid tumor; temozolomide; phenotype; gene overexpression; gene amplification; gene expression; epidermal growth factor receptor; sonic hedgehog protein; genotype; notch receptor; editorial; angiogenesis; necrosis; protein p53; cpg island; glioblastoma; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; cancer relapse; methylated dna protein cysteine methyltransferase; cyclin dependent kinase inhibitor 2a; second cancer; gene dosage; astrocytoma; giant cell; chemoradiotherapy; tumor necrosis factor; isocitrate dehydrogenase; i kappa b
|
